United States Patent 8,895,245: Claim Scope, Competitor Positioning, and Landscape
US Drug Patent 8,895,245 is directed to a companion diagnostic logic embedded in a treatment method for EZH2-driven cancer biology. The claims require (i) detecting a specific EZH2 Y641 non-tyrosine substitution in patient nucleic acid and (ii) administering an EZH2 inhibitor when that alteration is detected, with downstream constraints tied to how the nucleic acid is amplified/detected.
What is the core invention claim scope in US 8,895,245?
Claim 1 is the only independent claim and defines a closed-loop method
Claim 1 (method for treating cancer) contains a sequential chain of five functional steps plus explicit molecular definitions:
-
Obtain nucleic acid from a subject with cancer
- “providing a nucleic acid sample from a biological sample from a subject having a cancer”
-
Hybridize using an EZH2 Y641 mutation-containing sequence context
- contacting with at least one primer hybridizing to nucleic acid encoding EZH2
- primer hybridization is tied to: “sample comprises at least a portion of SEQ ID NO: 7 or the sequence complementary to SEQ ID NO: 7”
- the sample “comprises at least one mutation including a mutation at the nucleotides encoding position Tyr641 (Y641) of EZH2 of SEQ ID NO: 1”
- the mutation “increases EZH2 trimethylation of Lys27 of histone H3 (H3-K27)”
-
Amplify a portion that encodes a non-tyrosine residue at Y641
- “amplifying a portion of the nucleic acid molecule containing nucleotides encoding an amino acid other than tyrosine at position Y641 of EZH2”
-
Detect the amplified product and use it as the responsiveness indicator
- “detecting the amplified nucleic acid molecule”
- detection rule: if amplified nucleic acid encodes an amino acid other than tyrosine at Y641, then “indicates that the subject is responsive to an inhibitor of EZH2”
-
Administer an EZH2 inhibitor
- “administering a therapeutically effective amount of an EZH2 inhibitor to the subject”
Structural takeaway: Claim 1 ties test result (Y641 non-tyrosine substitution) to treatment selection (administer EZH2 inhibitor). That is the scope anchor.
How narrow is the molecular requirement on EZH2 Y641?
The Y641 requirement is explicit and functional
Claim 1 requires:
- a mutation “at the nucleotides encoding position Y641”
- and that this mutation “increases EZH2 trimethylation of Lys27 of histone H3”
- plus later that amplification/detection is specifically for “an amino acid other than tyrosine at position Y641.”
So, even within “Y641 mutants,” the claim is built around non-tyrosine substitutions.
Dependent claim 6 selects specific substitutions
Claim 6 limits the Y641 mutation to:
Implication for scope: Claim 1 is broader than claim 6 (any non-tyrosine at Y641), while claim 6 is a narrower subset.
What claims specify the cancer types covered?
Dependent claim 2 limits to a set of cancers
Claim 2 limits the subject cancer (or risk status) to:
- leukemia
- melanoma
- lymphoma
It also covers subjects “at risk of developing” these cancers.
Dependent claim 5 narrows lymphoma subtypes
Claim 5 further limits lymphoma selection to:
- Non-Hodgkin’s lymphoma
- follicular lymphoma
- diffuse large B-cell lymphoma (DLBCL) of germinal center B cell-like (GCB) subtype
Scope consequence: If competitors aim at other tumor settings (outside those categories) or non-lymphoma solid tumors, the claim set as provided does not map directly.
How are the companion diagnostic steps constrained?
Claims 3 and 4 control the detection format
- Claim 3: detecting is “performed by targeted resequencing.”
- Claim 4: targeted resequencing includes “amplifying … with at least one polymerase chain reaction (PCR) primer.”
What this means operationally
- A workflow that does not use “targeted resequencing” as the detection method will not fall cleanly within claim 3.
- A workflow that does targeted sequencing but avoids the specific PCR primer amplification framing in claim 4 may still avoid claim 4, while claim 3 alone could still capture the method if it meets “targeted resequencing” language.
Claim 1 also hard-codes primer hybridization sequence anchor
Claim 1 includes an additional constraint: the nucleic acid sample “comprises at least a portion of SEQ ID NO: 7 or the sequence complementary to SEQ ID NO: 7.”
This means competitors using different primer targets or sample design that does not involve that SEQ ID NO: 7-defined region can reduce literal fit on claim 1’s primer-contact step.
What does “responsive to an EZH2 inhibitor” require?
The claim uses genotype as the response predicate
Claim 1 defines responsiveness as:
- if detection shows “nucleotides encoding an amino acid other than tyrosine at position Y641,”
- then “indicates that the subject is responsive to an inhibitor of EZH2.”
This creates a genotype-to-treatment linkage without requiring explicit clinical outcome thresholds inside the claim text.
What are the treatment formulation constraints?
Claims 7 and 8 define the inhibitor nature
- Claim 7: inhibition of EZH2 is “selective inhibition.”
- Claim 8: the EZH2 inhibitor is a “small molecule.”
Scope consequence: The claim set (as provided) excludes, at least as written, nonsmall-molecule modalities or broad-spectrum inhibition that is not “selective.”
Claim coverage map (what is required vs. optional across the set)
| Claim element |
Claim 1 (independent) |
Claim 2 |
Claim 3 |
Claim 4 |
Claim 5 |
Claim 6 |
Claim 7 |
Claim 8 |
| Treat cancer in subject |
Required |
Limited |
Required (via claim 1) |
Required (via claim 1) |
Limited |
Required |
Required |
Required |
| Cancer types specified |
No |
Leukemia/melanoma/lymphoma |
No |
No |
NHL/follicular/DLBCL-GCB |
No |
No |
No |
| Nucleic acid from biological sample |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
| Primer hybridizes to EZH2 encoding nucleic acid |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
| SEQ ID NO: 7 sequence portion/complement required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
| EZH2 Y641 mutation present |
Required |
Required |
Required |
Required |
Required |
Required (subset) |
Required |
Required |
| Y641 is non-tyrosine for detection logic |
Required |
Required |
Required |
Required |
Required |
Subset |
Required |
Required |
| Amplify EZH2 Y641 non-tyrosine segment |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
| Detect amplified nucleic acid |
Required |
Required |
“targeted resequencing” |
targeted resequencing includes PCR primers |
Required |
Required |
Required |
Required |
| Genotype indicates responsiveness |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
| Administer EZH2 inhibitor |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
Required |
| Inhibitor selective |
No |
No |
No |
No |
No |
No |
Required |
Required |
| Inhibitor small molecule |
No |
No |
No |
No |
No |
No |
No |
Required |
| Specific Y641 substitutions |
No |
No |
No |
No |
No |
Required (Y641F/H/N/S) |
No |
No |
| Lymphoma subtype list |
No |
No |
No |
No |
Required |
No |
No |
No |
What is the competitive risk profile for this patent?
Highest-likelihood infringement scenarios
Competitors that do both of the following are most exposed:
- Use a diagnostic decision rule that treats based on presence of EZH2 Y641 non-tyrosine alterations.
- Implement the method using targeted resequencing (and PCR primer amplification) and/or primer designs that fall within the SEQ ID NO: 7-defined hybridization step.
Lower-likelihood infringement scenarios (based on the claim text provided)
- Testing that does not use “targeted resequencing” as framed in claim 3.
- Genotyping that targets EZH2 but does not include the claimed SEQ ID NO: 7 region for the primer hybridization step.
- Treatment decisions that do not explicitly follow the “Y641 non-tyrosine indicates responsiveness” logic as a claimed method step.
- Using non-small-molecule inhibitors or non-selective EZH2 inhibition (relevant to claims 7 and 8).
Landscape: how US 8,895,245 fits into the EZH2 diagnostic-treatment ecosystem
Positioning relative to EZH2 biology
This patent centers on EZH2 oncogenic alterations involving:
- Y641 mutations and downstream epigenetic effects via
- increased H3-K27 trimethylation.
By requiring detection of Y641 non-tyrosine substitutions and linking them to sensitivity to EZH2 inhibitors, it aligns with a widely pursued clinical model: genotype-driven patient selection for EZH2-targeted therapy.
Industrial structure implications
The claim set has two technical “gates” that map to common product architectures:
- Companion diagnostic gate (targeted resequencing + PCR, primer hybridization, Y641 non-tyrosine call)
- Therapeutic selection gate (selective EZH2 inhibition using a small molecule)
This makes the patent particularly relevant where a company develops:
- an integrated “test-then-treat” program, or
- lab-developed targeted sequencing followed by EZH2 inhibitor prescribing under a protocol.
Scope boundaries that matter for R&D and licensing
Boundary 1: Y641 non-tyrosine only
Claim 1 is anchored to “amino acid other than tyrosine at position Y641.” That is not:
- Y641 retention (wild type)
- Y641 changes to tyrosine (not plausible)
- other EZH2 driver sites
Boundary 2: targeted resequencing requirement appears in claim 3
If a product uses broader NGS approaches that do not meet “targeted resequencing” as construed, literal coverage may narrow to the subset that is clearly “targeted resequencing.”
Boundary 3: primer hybridization includes SEQ ID NO: 7
The SEQ ID NO: 7 anchor is a strong literal constraint at the step level. If primer sets and assay regions are redesigned away from that defined region, claim 1’s primer hybridization step can be harder to meet literally.
Boundary 4: inhibitor definition narrows in dependent claims
Even if claim 1 is met, dependent claims narrow the inhibitor to:
- selective inhibition (claim 7)
- small molecule (claim 8)
These become leverage points in patent-infringement analysis and in license scope negotiation.
Business impact summary: where the patent likely bites
| Business line |
Where 8,895,245 matters most |
Why |
| Companion diagnostic development |
Protocols using targeted resequencing to call EZH2 Y641 non-tyrosine |
Claim 3 and claim 4 |
| Assay design |
Primer region selection tied to SEQ ID NO: 7 |
Claim 1 primer hybridization step |
| Clinical trial enrichment |
Genotype-driven assignment to EZH2 inhibitor arms using Y641 non-tyrosine responsiveness logic |
Claim 1 “indicates responsiveness” + treatment step |
| Drug commercialization |
Small-molecule selective EZH2 inhibitors used in labeled or off-label patient subsets defined by Y641 non-tyrosine detection |
Claim 7 and claim 8 |
Key Takeaways
- US 8,895,245 claim 1 is a genotype-to-treatment method: detect EZH2 Y641 non-tyrosine mutations (with the assay primer/hybridization and SEQ ID NO: 7 constraints) and administer an EZH2 inhibitor when the alteration is detected.
- Claim 3 and 4 lock in the companion diagnostic format: detection must be by targeted resequencing, including PCR primer amplification.
- Claim 2 and claim 5 define clinical scope: leukemia, melanoma, lymphoma, with lymphoma narrowed to NHL, follicular lymphoma, and DLBCL GCB subtype.
- Claim 6 restricts Y641 substitution identities to Y641F/H/N/S.
- Claims 7 and 8 narrow the therapeutic modality to selective and small-molecule EZH2 inhibitors.
FAQs
1) Does US 8,895,245 cover EZH2 mutations other than Y641?
No. Claim 1 requires a mutation at EZH2 Y641 and requires detection logic for an amino acid other than tyrosine at that position.
2) Is the detection method limited to PCR-based assays?
Claim 1 requires amplification and detection. Claim 4 adds that targeted resequencing includes amplification with PCR primers. Claim 3 requires targeted resequencing for the detection step.
3) If a test is targeted sequencing but not “targeted resequencing,” is it covered?
The text ties detection to “performed by targeted resequencing” in claim 3. If a method is not within that framing, it may avoid claim 3’s limitations. The literal scope depends on claim construction.
4) Are Y641F/H/N/S specifically required?
No for claim 1. Claim 6 specifies Y641F, Y641H, Y641N, and Y641S as a dependent subset.
5) What kind of EZH2 inhibitors are covered?
Claim 7 requires selective inhibition, and claim 8 requires the inhibitor is a small molecule.
References
[1] United States Patent 8,895,245. (Claims as provided in user prompt: claim 1-8).
